Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic test
Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic test"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
US researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment,
without a genetic test. US researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild
cognitive impairment, without a genetic test. Researchers from the University Of California discovered that for people who carry a specific genetic variation, the K-variant of
butyrylcholinesterase, or BChE-K donezpezil, could accelerate cognitive decline. The study has been published in Journal of Alzheimer's Disease. Mild cognitive impairment is a
transitional state between normal age-related changes in cognition and dementia. Because many people with the condition display symptoms similar to those caused by Alzheimer's disease,
some physicians prescribe donepezil, which is marketed under the brand name Donepezil was tested as a possible treatment for mild cognitive impairment in a large, federally funded study
published in 2005, but it was not approved by the FDA. Still, doctors have often prescribed the drug "off-label" -- meaning that it is not approved for that specific disorder --
for their patients with mild cognitive impairment. The researchers looked at the association between BChE-K and changes in cognitive function. Using two tests that measure cognitive
impairment, the Mini-Mental State Examination and the Clinical Dementia Rating Sum of Boxes. The findings indicated that people with the genetic variation, who were treated with donepezil
had greater changes in their scores than those who took placebos. They also found that those who took donepezil had a faster cognitive decline than those who took the placebo. The findings
reinforce the importance of physicians discussing the possible benefits and risks of this treatment with their patients. (This article has not been edited by DNA's editorial team and is
auto-generated from an agency feed.)
Trending News
404 Error - Los Angeles TimesSorry! The page you were looking for cannot be found.The page may no longer exist or may have moved to another web addre...
Javascript support required...
Rnc day 3 features highly anticipated jd vance speech and a focus on foreign policyMILWAUKEE — The Republican National Convention’s third day will focus on foreign policy for its “Make America Strong Onc...
In this issue | Nature Reviews CancerYou have full access to this article via your institution. Download PDF This is the first-anniversary issue of _Nature R...
The reality of returning to work after maternity leave in a pandemicShortly before 5pm on 6 March 2020, I walked out of my office in Central London for the last time until, I assumed, Janu...
Latests News
Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic testUS researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, shou...
Stonewall moments: honoring icons in lgbtq+ activismMemorial Day Sale! Join AARP for just $11 per year with a 5-year membership Join now and get a FREE gift. Expires 6/4 G...
Mumbai: uno game turns fatal, man slashes friend's throat for 'cheating'The attacking youth was allegedly furious that his friend was cheating while playing the game which led to the brutal at...
Rahul gandhi constitutes steering committee for plenary sessionCongress president Rahul Gandhi has constituted a steering committee for the forthcoming Plenary Session. This announcem...
Cnbc interview with sir richard branson, founder, virgin group & chairman, virgin hyperloop one and sultan ahmed bin sulayem, group chairman & ceo, dp_Below is the transcript of an interview with CNBC's Middle East anchor, Hadley Gamble and Sir Richard Branson, Fou...